According to a study, a novel medication called enoblituzumab, a monoclonal antibody, is safe in men with aggressive prostate cancer and may promote clinical action against cancer across the body.
Women suffering from mental illness, neuropsychiatric disability, or substance addiction are less likely to undergo gynaecological screening tests for cervical cancer and are more than twice as likely to develop the disease.
A Duke Health research team has uncovered a collection of biomarkers that might help determine whether pancreatic cysts are likely to develop into cancer or stay benign.
According to the reports of the largest study, active monitoring of prostate cancer has the same high survival rates after 15 years as radiotherapy or surgery.
An advanced imaging approach is showing promise in improving prostate cancer detection by providing doctors with a clearer image of suspected tumours during the biopsy.
Basal cell carcinoma and squamous cell carcinoma, jointly known as keratinocyte carcinoma and the most prevalent types of cancer diagnosed in the United States, are thought to be preventable with simple laser skin treatments, according to new research.
Mutations in the gene that encodes for dystrophins have been linked to the devastating muscle-wasting illness DMD, which affects one out of every 5,000 boys born. Individuals with the illness usually live only into their 20s or 30s.
According to a recent study from the University of Gothenburg, the immunosuppressive medicine methotrexate (MTX) has been linked to an increased risk of three forms of skin cancer. Patients using the medicine have moderate to severe psoriasis; nonetheless, a risk increase for basal cell carc
Lung cancer is the main cause of cancer death in the United States and around the world. Low-dose chest computed tomography (LDCT) is suggested for monitoring persons aged 50 to 80 with a significant history of smoking or who actively smoke. Lung cancer screening with LDCT has been demonstra
A recent study finds that severe inflammation reduces the body's ability to eliminate malignant blood cells in persons with acute myeloid leukaemia (AML).
Researchers at The University of Texas MD Anderson Cancer Center have discovered a novel immunotherapy combination, targeting checkpoints in both T cells and myeloid suppressor cells.